Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas
- 1 May 2000
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 36 (8), 1026-1031
- https://doi.org/10.1016/s0959-8049(00)00048-4
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma.Journal of Clinical Oncology, 1997
- Logistic regression model of fotemustine toxicity combining independent phase II studiesCancer, 1996
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI Journal of the National Cancer Institute, 1993
- Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adultsCancer, 1993
- Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failureJournal of Neuro-Oncology, 1992
- Phase II study of fotemustine in recurrent supratentorial malignant gliomasEuropean Journal of Cancer and Clinical Oncology, 1991
- Successful chemotherapy for recurrent malignant oligodendrogliomaAnnals of Neurology, 1988
- Etoposide (VP-16-213) in malignant brain tumors: a phase II study.Journal of Clinical Oncology, 1984
- Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after SurgeryNew England Journal of Medicine, 1980
- Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomasJournal of Neurosurgery, 1978